Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 March 2019 | Story Rulanzen Martin | Photo Rulanzen Martin
CGAS staff with Jessica Lynn
From left: Ankia Bradfield, Sihle Salman, Jessica Lynn, Dr Nadine Lake, programme director, Gender Studies, and Dr Stephanie Cawood, director of CGAS after the talk.

For Jessica Lynn, a transgender activist, referencing the Butterfly to tell her journey, is the perfect metaphor to raise awareness of transgender issues. The Centre for Gender and Africa studies (CGAS) at the University of the Free State (UFS) hosted Lynn at a seminar titled, The Butterfly Project.

The CGAS invited Lynn in an effort to educate and inform students of her own experience as a parent living as a transgender woman. She is a global ambassador at the Kinsey Institute.

Coping mechanisms to escape reality

Born Jeffery Alan Butterworth in 1965, Lynn has become a world-renowned, dynamic and hard-hitting transgender activist. Lynn started her seminar off with: “Who here knows someone that is part of the transgender community?” It was evident that not many people know someone who is transgender. “In the United States only 16% of the population knows someone who is transgender,” she said.

“Everybody has their own story, just like I am only one of the 1.4 million transgender stories in the United States (US).” As a child of English immigrants to the US she was raised as a boy. “At a very young age I wanted to be girl,” she says, “but in 1969 it was not something that was spoken about..”

She started doing photography, painting and sports to stop the feelings she had to become a girl. She became obsessed with painting. “When I am painting that eagle I became that eagle in order to escape my reality.” She came out to her children as transgender during December 2009. She fully transitioned in 2010.

Lynn is the mother of three boys and was married to their biological mother. A botched Texas court restricted her access to her youngest child and to this day she has not been able to see her son.

Transgender discussions on rise in South Africa

“Transgender discussions have been less salient than conversations around homosexuality in South Africa,” said Dr Nadine Lake, programme director for Gender Studies at the UFS.  “But it is clear that raising awareness around transgender issues is starting to take more ground.”

Transgender identity and trans-body rights emerged during the #RhodesMustFall movement in 2015. “It was university students that were primarily driving the transformation agenda,” said Dr Lake.

The seminar on 20 February 2019 was an emotional, explosive and honest narrative of Jessica Lynn cocooning from Jeffrey Alan Butterworth to the phenomenal women she is today.

 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept